Early Risk Identification and Preventive Strategies for Hyperglycemia in HR+/HER2-Negative Advanced Breast Cancer

In this segment, Dr. Neil Iyengar moderates a discussion focused on hyperglycemia as a class-related adverse event across the PI3K/AKT/PTEN pathway in HR+/HER2-negative advanced breast cancer. Drawing on clinical experience with earlier PI3K inhibitors, the panel explores how clinicians identify patients at higher risk for developing hyperglycemia prior to initiating AKT pathway–targeted therapy. Panelists discuss key metabolic risk factors, including preexisting diabetes, impaired glucose tolerance, obesity, and concomitant medications, and how these considerations inform baseline assessment and early monitoring strategies. The conversation emphasizes the importance of proactive planning, patient education, and close follow-up during the initial weeks of treatment to mitigate risk and prevent severe metabolic complications. This segment highlights how early risk recognition and preventive approaches can support safer treatment initiation, reduce the likelihood of treatment interruption, and improve overall tolerability in real-world clinical practice.